July 9 (Reuters) - Benitec Biopharma Ltd BLT.AX :
* LICENSED TO AXOVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS FOR BB-301 INTENDED FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY
* BENITEC TO RECEIVE UPFRONT CASH PAYMENT OF US$10 MILLION WITH ADDITIONAL CASH PAYMENTS TOTALLING US$17.5 MILLION
* BENITEC WILL RETAIN 30% OF NET PROFITS ON WORLDWIDE SALES OF AXO-AAV-OPMD